Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study

Varenna, M.; Zucchi, F.; Failoni, S; Becciolini, Andrea; Berruto, Massimo

doi:10.1093/rheumatology/kev123

Cited by 53 publications

(37 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We tested whether osteoclast enzymes released during bone resorption, cath-K and TRAcP5b 38,39 , could serve as markers of subchondral osteoclast activity. Our data, linking osteoclast activity, as reflected by serum TRAcP5b, with OA pain provide a clear biological mechanism that could explain the reported analgesic benefit of anti-resorptives such as bisphosphonates in human 40,41 and rodent OA 7 . We also observed at baseline, an association of serum TRAcP5b with subchondral bone sclerosis as well as with WOMAC pain scores, further suggesting a link between subchondral bone remodelling and pain generation in OA.…”

Section: Discussionmentioning

confidence: 63%

Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA

Nwosu

Allen

Wyatt

et al. 2017

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

(2017) Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA. Osteoarthritis and Cartilage, 25 (6). pp. 858-865. ISSN 1522-9653 Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/40543/1/1-s2.0-S1063458417300092-main_accepted %20manuscript%20copy.pdf Copyright and reuse:The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions. This article is made available under the Creative Commons Attribution Non-commercial No Derivatives licence and may be reused according to the conditions of the licence. For more details see: http://creativecommons.org/licenses/by-nc-nd/2.5/ A note on versions:The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.For more information, please contact eprints@nottingham.ac.uk This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Two putative osteoclast biomarkers were measured in sera: TRAcP5b and cathepsin K. 30Medial tibia plateaux were donated at knee arthroplasty for symptomatic OA (n=84) or from Results 35Serum TRAcP5b activity, but not cathepsin K-immunoreactivity, was associated with density 36 of TRAcP-positive osteoclasts in the subchondral bone of medial tibia plateaux. TRAcP-37 positive osteoclasts were more abundant in people with symptomatic OA compared to 38 controls. Serum TRAcP5b activity was associated with baseline pain and pain change.

show abstract

Section: Discussionmentioning

confidence: 63%

Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA

Nwosu

Allen

Wyatt

et al. 2017

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

show abstract

“…According to the results of a randomized, double-blind, placebo-controlled study, daily 6 Clinical Medicine Insights: Therapeutics 100 mg intravenous neridronate injections for 10 days significantly reduced pain and improved the quality of life of patients with acute pain caused by knee OA compared with the placebo. Furthermore, the neridronate group exhibited a significant decrease in bone marrow lesions evaluated by MRI, 49 suggesting a possible structural effect based on the hypothesis that altered bone metabolism plays a role in the pathogenesis of OA. [50][51][52][53] …”

Section: Osteoarthritismentioning

confidence: 94%

Neridronate: From Experimental Data to Clinical Use

Corrado

Colìa

Cantatore

2017

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Neridronate is an amino-bisphosphonate that has been officially approved as a treatment for osteogenesis imperfecta, Paget’s disease of bone and type I complex regional pain syndrome in Italy. Neridronate is administered either intravenously or intramuscularly; thus, it represents a valid option for both cases with contraindications to the use of oral bisphosphonates and cases with contraindications or an inability to receive an intravenous administration of these drugs. Furthermore, although the official authorized use of neridronate is limited to only 3 bone diseases, many experimental and clinical studies support the rationale for its use and provide evidence of its effectiveness in other pathologic bone conditions that are characterized by altered bone remodelling.

show abstract

“…A randomized controlled trial of vitamin D supplement vs placebo in more than 400 patients with KOA did not show significant differences in either MRI-measured tibial cartilage volume change or WOMAC knee pain change over 2 years 59 . In contrast a study of intravenous Neridronate was found to significantly improve clinical symptoms compared to placebo and to reduce BMLs after 2 and 4 months in patients with symptomatic KOA 60 . Intraarticular injection of Sprifermin was reported to increase cartilage thickness or reduce cartilage loss in KOA 61 and intraarticular allogeneic bone marrow mesenchymal stem cell therapy showed indication of clinical efficacy and improved cartilage T2map status compared to intraarticular hyaluronic acid 62 .…”

Section: Treatment Responsementioning

confidence: 78%